Boston Scientific Corporation [NYSE: BSX] price plunged by -0.02 percent to reach at -$0.01. The company report on January 3, 2023 that Boston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2022 Results.
Boston Scientific Corporation (NYSE: BSX) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 in San Francisco, California. Mike Mahoney, chairman and chief executive officer, will present at approximately 8:15 a.m. PST / 11:15 a.m. EST. Mahoney will be joined by Dan Brennan, executive vice president and chief financial officer, Kenneth Stein, M.D., senior vice president and chief medical officer, Cardiac Rhythm Management, and Lauren Tengler, vice president, Investor Relations, in a question-and-answer session with the host analyst.
On Wednesday February 1, 2023, Boston Scientific will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2022. The call will begin at 8:00 a.m. EST, hosted by Mike Mahoney and Dan Brennan. The company will issue a news release announcing financial results for the fourth quarter on February 1 prior to the conference call.
A sum of 6097676 shares traded at recent session while its average daily volume was at 6.85M shares. Boston Scientific Corporation shares reached a high of $45.945 and dropped to a low of $45.44 until finishing in the latest session at $45.84.
The one-year BSX stock forecast points to a potential upside of 10.71. The average equity rating for BSX stock is currently 1.80, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Boston Scientific Corporation [BSX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BSX shares is $51.34 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BSX stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for Boston Scientific Corporation shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 22, 2022. While these analysts kept the previous recommendation, Citigroup raised their target price to Buy. The new note on the price target was released on December 20, 2022, representing the official price target for Boston Scientific Corporation stock. Previously, the target price had yet another raise to $49, while Barclays analysts kept a Overweight rating on BSX stock.
The Average True Range (ATR) for Boston Scientific Corporation is set at 0.82, with the Price to Sales ratio for BSX stock in the period of the last 12 months amounting to 5.21. The Price to Book ratio for the last quarter was 3.72, with the Price to Cash per share for the same quarter was set at 0.24. Price to Free Cash Flow for BSX in the course of the last twelve months was 117.89 with Quick ratio for the last quarter at 0.90.
BSX Stock Performance Analysis:
Boston Scientific Corporation [BSX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.43. With this latest performance, BSX shares dropped by -0.52% in over the last four-week period, additionally plugging by 20.63% over the last 6 months – not to mention a rise of 6.68% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BSX stock in for the last two-week period is set at 50.83, with the RSI for the last a single of trading hit 49.36, and the three-weeks RSI is set at 52.57 for Boston Scientific Corporation [BSX]. The present Moving Average for the last 50 days of trading for this stock 45.32, while it was recorded at 45.57 for the last single week of trading, and 41.65 for the last 200 days.
Insight into Boston Scientific Corporation Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Boston Scientific Corporation [BSX] shares currently have an operating margin of +16.17 and a Gross Margin at +62.76. Boston Scientific Corporation’s Net Margin is presently recorded at +8.75.
Return on Equity for this stock inclined to 6.51, with Return on Assets sitting at 3.30.
Boston Scientific Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 1.40.
BSX Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BSX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Boston Scientific Corporation go to 10.77%.
Boston Scientific Corporation [BSX] Insider Position Details
There are presently around $59,445 million, or 94.60% of BSX stock, in the hands of institutional investors. The top three institutional holders of BSX stocks are: BLACKROCK INC. with ownership of 127,361,993, which is approximately 0.874% of the company’s market cap and around 0.20% of the total institutional ownership; VANGUARD GROUP INC, holding 116,886,236 shares of the stock with an approximate value of $5.36 billion in BSX stocks shares; and MASSACHUSETTS FINANCIAL SERVICES CO /MA/, currently with $3.85 billion in BSX stock with ownership of nearly 0.581% of the company’s market capitalization.
Positions in Boston Scientific Corporation stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 423 institutional holders increased their position in Boston Scientific Corporation [NYSE:BSX] by around 55,701,893 shares. Additionally, 375 investors decreased positions by around 51,461,840 shares, while 150 investors held positions by with 1,189,636,280 shares. The mentioned changes placed institutional holdings at 1,296,800,013 shares, according to the latest SEC report filing. BSX stock had 80 new institutional investments in for a total of 5,442,830 shares, while 90 institutional investors sold positions of 19,502,877 shares during the same period.